Anar al contingut
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avançada
  • Vorinostat does not improve ou...
  • Citar
  • Enviar aquest missatge de text
  • Enviar per correu electrònic aquest
  • Imprimir
  • Exportar registre
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Enllaç permanent
Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Dades bibliogràfiques
Autors principals: Craddock, C, Houlton, A, Ferguson, P, Raghavan, M, Fox, S, Dudley, L, Quek, L, Cavenagh, J, Dennis, M, McMullin, M, Pillai, S, Kelly, R, Siddique, S, Wheatley, K, Vyas, P
Format: Conference item
Publicat: American Society of Hematology 2016
  • Fons
  • Descripció
  • Ítems similars
  • Visualització del personal

Ítems similars

  • Molecular predictors of response to azacitidine therapy: the results of the UK trials acceleration programme RAVVA study
    per: Craddock, C, et al.
    Publicat: (2017)
  • Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
    per: Craddock, C, et al.
    Publicat: (2017)
  • Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
    per: Craddock, C, et al.
    Publicat: (2013)
  • Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
    per: Craddock, C, et al.
    Publicat: (2013)
  • INDUCTION OF A CDS+ T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
    per: Goodyear, O, et al.
    Publicat: (2010)

Opcions de cerca

  • Historial de cerca
  • Cerca avançada

Trobar-ne més

  • Explorar el catàleg
  • Explorar alfabèticament
  • Explora canals
  • Bibliografia recomanada
  • Nous ítems

Necessites ajuda?

  • Consells de cerca
  • Pregunteu al bibliotecari
  • FAQs